Jiangsu Hengrui Pharmaceuticals Co., Ltd. released its monthly return for the period ended 31 March 2026, detailing marginal share-capital movements centred on A-share buybacks and confirming adequate public float for its Hong Kong-listed H shares.
Authorised and Issued Share Capital • Total authorised share capital remained unchanged at 6.64 billion shares with a par value of RMB1 each, equivalent to RMB6.64 billion. • Hong Kong-listed H shares: issued volume held steady at 258.20 million shares. • Shanghai-listed A shares: issued shares declined by 1.25 million to 6.37 billion, reflecting share repurchases moved into treasury. Treasury A shares consequently rose to 6.79 million.
A-Share Repurchase Activity • Hengrui Pharma repurchased 623,000 A shares on 2 March at RMB54.83 per share and 630,000 A shares on 3 March at RMB53.94 per share, totalling 1.25 million shares for the month. • All repurchased shares were retained as treasury stock, earmarked for existing employee stock-ownership schemes.
Employee Stock-Ownership Schemes • The 2022-2025 A Share Employee Stock Ownership Schemes collectively hold an entitlement to issue or transfer up to 6.79 million shares, unchanged during the month.
Public Float Compliance for H Shares • The H-share public float satisfied Listing Rule thresholds, representing 3.89 % of the class and carrying a market value of HK$18.77 billion as of 31 March 2026.
Capital Structure Snapshot (31 March 2026) • Authorised shares: 6.64 billion • Issued shares – A class: 6.37 billion (treasury: 6.79 million) • Issued shares – H class: 258.20 million (no treasury shares)
No share options, warrants, convertibles or other equity instruments were exercised, issued or cancelled during the month, and no changes occurred in the company’s registered capital or par value.
Comments